Search Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

CytomX Therapeutics, Inc. today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.

CytomX Therapeutics, Inc., a leader in the field of masked, conditionally activated biologics, reported first quarter 2024 financial results and provided a business update.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US and Canada) for CytomX’s first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

CytomX Therapeutics, Inc. today announced that management will participate in the following investor conferences in March.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.

CytomX Therapeutics, Inc. announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.

CytomX Therapeutics, Inc. today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.